

Filed On Behalf Of:

Novartis AG

By:

Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

NOVARTIS AG,
Patent Owner.

Case IPR2017-01063
Patent 9,006,224

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(2)**

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned states that Novartis AG (“Novartis” or “Patent Owner”) owns U.S. Patent No. 9,006,224 (“the ’224 Patent”). Novartis is the real party-in-interest in IPR2017-01063.

RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

The ’224 Patent has been asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 15-474-RGA (D. Del.); and (2) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-475-RGA (D. Del.) (order dismissing proceeding filed October 15, 2015).

The ’224 Patent is also the subject of the following Petitions for *Inter Partes* Review: Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-01461 (P.T.A.B.) (institution granted February 15, 2017); Novartis AG v. Roxane Labs., Inc., *Inter Partes* Review No. 2016-01461 (P.T.A.B.) (institution denied February 13, 2017); Novartis AG v. West-Ward Pharms. Int’l Ltd., *Inter Partes* Review No. 2017-01078 (P.T.A.B.) (petition filed March 13, 2017, institution decision pending).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis designates Nicholas N. Kallas (Reg. No. 31,530) as lead counsel and Laura K. Fishwick (Reg. No. 69,907) as back-up counsel.

A power of attorney from Novartis is being submitted with this Notice.

SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

Novartis may be served electronically using the following e-mail address:

ZortressAfinitorIPR@fchs.com

Novartis may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Nicholas N. Kallas
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104
Telephone: (212) 218-2100
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: March 24, 2017

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas

New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of Patent Owner's Mandatory Notices Under 37 C.F.R. § 42.8(a)(2) was served on March 24, 2017 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Kevin Laurence (klaurence@lpiplaw.com)

Matthew Phillips (mphilips@lpiplaw.com)

Tyler C. Liu (tliu@agpharm.com)

Dated: March 24, 2017

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100